XML 63 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Fair value of financial instruments and marketable securities - Narrative (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
Jun. 29, 2020
USD ($)
Apr. 29, 2020
USD ($)
Dec. 31, 2019
USD ($)
May 31, 2019
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
Aug. 31, 2015
USD ($)
$ / shares
Financial assets and liabilities measured at fair value on recurring basis                      
Marketable Securities, Realized Gain (Loss)   $ 200,000   $ 200,000              
Deferred consideration payable   2,384,000   2,384,000       $ 40,000,000      
Unrealized gain (loss) on equity investment       (1,600,000) $ 129,000            
Investment In MRI   $ 4,600,000   4,600,000              
Purchase of convertible debt investment $ 10,000,000.0     $ 10,000,000 0            
Conversion price per share (in dollars per share) | $ / shares   $ 6.00   $ 6.00              
Debt instrument, convertible, period       5 years              
Unrealized loss       $ 700,000              
Marketable securities   $ 340,430,000   340,430,000       398,535,000      
Non-cash stock consideration, acquisition       42,869,000 0            
Operating Expenses   262,512,000 $ 124,280,000 423,762,000 247,003,000            
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset   (7,680,000) (5,300,000) $ (8,580,000) (26,460,000)            
Debt Securities, Available-for-sale, Unrealized Gain   $ 2,100,000                  
Common stock                      
Financial assets and liabilities measured at fair value on recurring basis                      
Issuance of common stock related to rights exchange (in shares) | shares   2,821,176   2,821,176              
Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Liability value   $ 136,100,000 277,400,000 $ 136,100,000 277,400,000     290,500,000   $ 257,040,000  
SARs                      
Financial assets and liabilities measured at fair value on recurring basis                      
Liability value   0 $ 1,960,000 0 $ 1,960,000     3,186,000   $ 3,814,000  
3.00% Convertible senior notes due 2022 | Convertible debt                      
Financial assets and liabilities measured at fair value on recurring basis                      
Principal   150,000,000   150,000,000       150,000,000     $ 150,000,000.0
Interest rate ( as a percent )                     3.00%
Fair value of convertible notes   175,200,000   175,200,000       171,200,000      
Conversion price per share (in dollars per share) | $ / shares                     $ 56.34
1.50% Convertible senior notes due 2026 | Convertible debt                      
Financial assets and liabilities measured at fair value on recurring basis                      
Principal   $ 287,500,000   $ 287,500,000       $ 287,500,000      
Interest rate ( as a percent )   1.50%   1.50%       1.50%      
Fair value of convertible notes   $ 343,800,000   $ 343,800,000       $ 335,000,000.0      
Conversion price per share (in dollars per share) | $ / shares   $ 52.52   $ 52.52              
Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Development milestone payments which the entity is obligated to pay   $ 40,000,000.0   $ 40,000,000.0     $ 40,000,000.0        
Net sales amount             $ 150,000,000.0        
Deferred consideration payable   2,400,000   2,400,000              
Non-cash stock consideration, acquisition   36,900,000                  
Milestone Payment Obligations           $ 174,000,000.0          
Gain Of Settlement, Development Milestones   700,000                  
Loss Of Settlement, Regulatory Milestones   11,300,000                  
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset   1,000,000.0                  
Contingent Consideration, Transaction Fees   $ 2,000,000.0   $ 2,000,000.0              
Agilis | Common stock                      
Financial assets and liabilities measured at fair value on recurring basis                      
Issuance of common stock related to rights exchange (in shares) | shares       2,821,176              
Agilis | Minimum                      
Financial assets and liabilities measured at fair value on recurring basis                      
Product sales   2.00%   2.00%     2.00%        
Development milestone payments which the entity is obligated to pay           37,600,000          
Agilis | Maximum                      
Financial assets and liabilities measured at fair value on recurring basis                      
Product sales   6.00%   6.00%     6.00%        
Development milestone payments which the entity is obligated to pay   $ 60,000,000.0   $ 60,000,000.0   $ 40,000,000.0          
Priority review voucher amount       535,000,000.0              
Net sales amount   150,000,000.0   150,000,000.0              
Non-collaborative Arrangement Transactions | Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Development milestone payments which the entity is obligated to pay   40,000,000.0   40,000,000.0              
Recurring basis | Total                      
Financial assets and liabilities measured at fair value on recurring basis                      
Estimated fair value of deferred consideration payable   2,384,000   2,384,000       40,000,000      
Liability value   89,600,000   89,600,000       65,800,000      
Marketable securities               $ 398,535,000      
Common stock                      
Financial assets and liabilities measured at fair value on recurring basis                      
Shares owned                 $ 4,000,000.0    
Fair value of shares (in dollars per share) | $ / shares                 $ 3.10    
Unrealized gain (loss) on equity investment   100,000   1,600,000              
Deferred consideration payable | Recurring basis | Total                      
Financial assets and liabilities measured at fair value on recurring basis                      
Marketable securities   $ 9,251,000   $ 9,251,000              
Development and Regulatory Milestone | Probability of Success [Member] | Minimum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input   0.25   0.25       0.25      
Development and Regulatory Milestone | Probability of Success [Member] | Maximum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input   0.94   0.94       0.94      
Development and Regulatory Milestone | Probability of Success [Member] | Weighted Average [Member] | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input   0.43   0.43              
Development and Regulatory Milestone | Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Liability value   $ 136,100,000   $ 136,100,000       $ 290,500,000      
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Minimum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input               0.022      
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Maximum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input               0.047      
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Weighted Average [Member] | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input   0.054   0.054              
Liability, Net Sales Milestones and Royalties [Member] | Probability of Success [Member] | Minimum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input   0.25   0.25       0.25      
Liability, Net Sales Milestones and Royalties [Member] | Probability of Success [Member] | Maximum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input   0.94   0.94       0.89      
Liability, Net Sales Milestones and Royalties [Member] | Probability of Success [Member] | Weighted Average [Member] | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input   0.50   0.50              
Liability, Net Sales Milestones and Royalties [Member] | Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Liability value   $ 89,600,000   $ 89,600,000       $ 65,800,000      
Liability, Net Sales Milestones and Royalties [Member] | Agilis | Measurement Input, Discount Rate | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Alternative Investment, Measurement Input   0.120   0.120       0.145